Miner Company
Big Pharma Is Buying — Why Biotech Stocks Could Outperform in 2026
Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum. After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.
Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum. After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.